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ABSTRACT 
TDP2 is a 5’-tyrosyl DNA phosphodiesterase important for the repair of DNA adducts 
generated by non-productive (abortive) activity of topoisomerase II. TDP2 facilitates 
therapeutic resistance to topoisomerase poisons, which are widely used in the treatment of 
a range of cancer types. Consequently, TDP2 is an interesting target for the development of 
small molecule inhibitors that could restore sensitivity to topoisomerase-directed therapies. 
Previous studies identified a class of deazaflavin-based molecules that showed inhibitory 
activity against TDP2 at therapeutically useful concentrations, but their mode of action was 
uncertain. We have confirmed that the deazaflavin series inhibits TDP2 enzyme activity in a 
fluorescence-based assay, suitable for HTS-screening.  We have gone on to determine 
crystal structures of these compounds bound to a ‘humanised’ form of murine TDP2. The 
structures reveal their novel mode of action as competitive ligands for the binding site of an 
incoming DNA substrate, and point the way to generating novel and potent inhibitors of 
TDP2. 
(155 words) 
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INTRODUCTION 
TDP2 (also known as TTRAP [1] or EAPII [2]) is a 5’-tyrosyl DNA phosphodiesterase that 
can remove the covalently-attached abortive complexes generated by DNA Topoisomerase 
II (TOP2) when it is unable to complete its normal catalytic cycle [3, 4]. TDP2 has also been 
co-opted by picornaviruses as the ‘unlinkase’ that releases nascent RNA from its VPg 
protein primer during viral replication [5]. 
 
TOP2 generates transient double-strand breaks (DSBs) in genomic DNA that relieve 
torsional stress introduced during transcription and replication [6]. The mechanism of DNA 
strand cleavage by TOP2 involves formation of a covalent reaction intermediate between 
the side-chain of a catalytic tyrosine in the enzyme, and the 5’-phosphate at the site of the 
DNA-strand break. TOP2 functions as a dimer, and produces a staggered DSB, with the 
nicks in the two strands separated by four base pairs. Normally, following passage of a 
distal segment of duplex DNA through the break, TOP2 facilitates attack on the 
phosphotyrosyl bonds by the free 3’-OH at the nicks, resealing the break and releasing the 
enzyme.  In some circumstances TOP2 is unable to complete the reaction cycle, leaving it 
covalently attached to the DSB 5’- termini in a highly toxic, abortive, ‘cleavage complex’ that 
can severely disrupt replication and transcription. Fortunately, this type of DNA lesion is 
efficiently repaired, in part though the action of TDP2, which hydrolyses the phosphotyrosyl 
bond in a magnesium cofactor-dependent reaction, leaving ligatable 5’-phosphate moieties. 
 
TOP2 ‘poisons’ such as doxorubicin (adriamycin) are known to intercalate into DNA (PDB: 
1D12; [7]); amsacrine (mAMSA) and etoposide (VP-1) have also been demonstrated to 
bind selectively at the nick sites of a TOP2-DNA complex (PDB: 4G0U, 3QX3; [8]) and 
prevent resealing of the strands. These interactions promote the cumulative formation of 
abortive TOP2-DNA complexes, leading ultimately to cell death in rapidly proliferating cells. 
Consequently, TOP2 poisons are potent anticancer agents [9], and are currently used in the 
clinic either as monotherapies, or as components of combination therapies for a range of 
tumour types [10-12]. However, the abortive complexes promoted by TOP2-poisons can be 
rescued by the action of TDP2, so that variations in cellular TDP2 activity (natural or 
tumour-specific) can influence the clinical efficacy of these drugs, and are therefore an 
important determinant of response to chemotherapy in the individual patient and tumour.  
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Consequently, TDP2 has attracted interest as a target for small molecule inhibitors that 
might have utility in overcoming innate or acquired resistance to TOP2 poisons.  
 
A series of potent TDP2 inhibitors based on a deazaflavin scaffold have previously been 
described, but their molecular mode of action could not be determined and the rational 
exploitation of structure-activity relationships was consequently limited [13]. Using a 
‘humanised’ mouse TDP2 expression construct, we have now determined X-ray crystal 
structures of the catalytic domain of TDP2 in complex with deazaflavin inhibitors, revealing 
the unusual molecular interactions underpinning their mode of action. These results provide 
a platform for structure-based drug design that will greatly assist the future development of 
small molecule inhibitors of human TDP2. 
 
 
RESULTS 
Structure of the human TDP2 catalytic domain 
We obtained crystals of the catalytic domain of human TDP2 (FIGURE 1A; hTDP2CAT – 
residues 113-362), in its unliganded form, using protein expressed in Escherichia coli and 
purified using standard chromatographic procedures (see MATERIALS AND METHODS). 
The expression construct contains a single-point mutant – Cys273Ser – which removes a 
potentially reactive surface cysteine, and that in our hands significantly improved the 
expression levels and solubility of the recombinant protein.  
 
The structure of hTDP2CAT was determined by molecular replacement, with the catalytic 
domain of mouse TDP2 as a search model (PDB: 4GYZ). However, crystals of hTDP2CAT 
typically diffracted both poorly and anisotropically.  Through iterative screening of many 
crystals, we were eventually able to collect a dataset that could be truncated isotropically to 
a maximum resolution of 3.1 Å (see TABLE 1). The fold of the human protein is highly 
similar to that of mouse [14], worm [15], and zebrafish [15] (FIGURE 1B,C) but with some 
important differences – see expanded description below.  
 
Deazaflavin inhibitors of TDP2 
A series of small molecule deazaflavin inhibitors of human TDP2 have previously been 
described [13], with examples showing in vitro biochemical activity against the isolated 
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enzyme in the nanomolar concentration range (FIGURE 2A). However, the precise mode of 
action of these compounds was unclear, and in the absence of an experimentally-
determined binding site, the structure activity relationships (SAR) were difficult to 
rationalise.   
 
As the original HTS screens were performed with full-length human TDP2, we first sought 
to confirm binding of these compounds to hTDP2CAT by thermal denaturation [16].  Using 
the most potent reported deazaflavin – compound 163 [13] we observed a shift in the 
melting temperature (Tm) of hTDP2
CAT from 48.7°C in the unliganded state, to 51.5°C in the 
presence of compound 163 at a concentration of 300 μM.  These results are indicative of 
moderately tight binding of 163 to hTDP2CAT (FIGURE 2B). 
 
We also confirmed inhibition of catalytic activity by three deazaflavin compounds, by using 
a modified form of a fluorescence-based assay [17].  A phosphotyrosyl moiety conjugated 
to Fluorescein isothiocyanate was readily removed from the 5’ end of a single-stranded 
oligonucleotide substrate by hTDP2CAT in a dose-dependant manner (SUPPLEMENTARY 
FIGURE S1 A,B). We could subsequently determine Km for the oligonucleotide substrate 
(208 ± 23 nM), Kcat for the reaction under the experimental conditions tested (1.58 ± 0.06 
sec-1; FIGURE 2C), as well as IC50 values for each of the deazaflavins; 163: 19, 148: 103, 
149: 489 nM (FIGURE 2D). The IC50 rank order is in agreement with the previously reported 
EC50 values, which used full-length human TDP2 and BIOMOL Green as a 
detection/quantification agent [13]. 
 
Low resolution co-crystal structure of hTDP2CAT bound to 163 
As with the apo-hTDP2CAT crystals, co-crystals with 163 presented severe problems with 
anisotropy during data collection. Again, multiple crystals were screened before a dataset 
that could be truncated isotropically, to a maximum resolution of 3.4Å, was obtained 
(TABLE 1). Despite the low resolution, which prevents detailed characterisation of specific 
protein-drug interactions, clear difference electron density maps identified the binding site 
and general pose of this class of inhibitor bound to TDP2 (SUPPLEMENTARY FIGURE 
S2).  
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The experimentally determined binding-mode of 163 is surprisingly different from that 
predicted by molecular docking studies [13], in which the pyrimidodione ring of the tricyclic 
core, was hypothesised to bind to the magnesium cofactor – required for catalytic activity of 
TDP2 – and made few (if any) hydrogen bonds directly to the protein.   
 
Instead, our data indicate that the tricyclic deazaflavin core of 163 unexpectedly packs 
against an extended hydrophobic patch, formed by the side chains of Trp297, Thr299, 
Leu305, Ile 307, Cys311, Leu313 and Phe315, which lies at the mouth of the channel 
leading to the active site, more than 9Å from the catalytic Mg2+ ion bound by the carboxyl 
side chains of Asp122 and Glu152 (FIGURE 2E). 
 
Due to the persistently poor crystallisation behaviour of the human protein, and the need to 
characterise fully this unusual and unexpected binding mode of the deazaflavin inhibitor, we 
switched species and used the murine form of the enzyme (mTDP2CAT), which yielded well-
behaved crystals diffracting to high resolution; as in previous studies [14]. As a preliminary 
experiment we tested the ability of 163 to inhibit mTDP2CAT in a gel-based assay. 
Unexpectedly, whilst 163 readily inhibited the catalytic activity of hTDP2CAT – preventing 
conversion of 5’-phosphotyrosyl termini to 5’-phosphates on a DNA duplex substrate – it 
failed to inhibit the mouse protein (FIGURE 2F). 
 
Comparison of the mouse and human TDP2 amino acid sequences revealed substantial 
differences in a segment of polypeptide, denoted the ‘M7-motif’ [14], delimited by highly 
conserved ‘TWDT’ (amino acids 296-299 in humans) and ‘RFDR’ (aa 314-317) motifs.  A 
multiple amino acid sequence alignment of this region (FIGURE 3A) shows it to be 
conserved in length (14 residues) amongst different organisms, but poorly conserved in 
amino acid sequence and somewhat variable in conformation (FIGURE 3B). Significantly, 
the M7-motif maps to the binding site we observe for 163 in hTDP2CAT, where human TDP2 
residues Cys311 and Leu313, along with Ala309, coalesce to form a ‘hydrophobic-shelf’ on 
which the deazaflavin core of 163 sits. Replacement of Cys311 and Leu313 in hTDP2 with 
the equivalent residues Tyr321 and His323 in mTDP2 disrupts this hydrophobic-shelf and 
explains the resistance of the mouse enzyme to the deazaflavin-based inhibitors (FIGURE 
3C). 
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Development of a protein surrogate: m2hTDP2CAT 
Although hTDP2CAT is effectively inhibited by 163 and related deazaflavins, its poor 
crystallographic behaviour greatly limits the degree to which structure-led approaches can 
be used in order to optimise these compounds further for clinical development. Conversely, 
mTDP2CAT, while crystallographically well-behaved and able to yield high resolution 
structures, does not bind deazaflavin inhibitors due to sequence differences in the M7-motif. 
 
To overcome these problems, we designed a series of mutations in the M7-motif and 
associated structure, designed to ‘humanise’ the inhibitor-binding site of mTDP2 while 
retaining the favourable murine surface that facilitates well-ordered crystals. Rather than 
exchange the entire mouse M7-motif for that of the human protein, we decided as an initial 
approach only to ‘humanise’ the amino acids expected to be in the proximity of the bound 
compound, and not those which would simply point towards solvent.  We therefore created 
the expression construct m2hTDP2CAT (m2h = mouse-‘to’-human) by mutating the following 
mouse residues to their human equivalent: Glu242Gly, Gln278Arg, Tyr321Cys and 
His323Leu.  
 
The m2hTDP2CAT protein retained full phosphodiesterase activity, and consistent with our 
prediction that the resistance of the mouse protein to deazaflavins was due to the variant 
M7-motif, this activity in m2hTDP2CAT was inhibited by 163 (FIGURE 3D). As no further 
optimisation of the ‘humanised’ construct was therefore required, m2hTDP2CAT was used 
for all subsequent structural analyses. 
 
High-resolution co-crystal structure of m2hTDP2CAT bound to 163 
We were able to validate our approach, by determining the X-ray crystal structure of 
m2hTDPCAT bound to 163, at a resolution of 1.8 Angstrom (Table 1).  Superposition of the 
low resolution hTDP2CAT and high-resolution m2hTDP2CAT structures in complex with 163, 
confirms that the binding site is conserved across both proteins (SUPPLEMENTARY 
FIGURE S3). However, the higher resolution data obtained with the m2hTDP2CAT 
surrogate, allows a far more detailed characterisation of the interaction of the inhibitor with 
the TDP2 catalytic domain (FIGURE 4A, SUPPLEMENTARY FIGURE S2). 
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The guanidinium head group of Arg276† is involved in an extensive hydrogen-bond network, 
including both carbonyl and nitrogen groups of the 163 pyrimidodione ring, as well as the 
backbone carbonyl and side chain (via a water molecule) of Asp 277. As in the fully human 
protein, amino acids of the M7-motif coalesce to form the ‘hydrophobic shelf’, which permits 
extensive van der Waals interactions with the tricyclic deazaflavin core; these residues 
include Trp307, Ile317, Ala319, Cys321‡, Leu323 and Phe325 (FIGURE 3A).  The tetrazole 
R1 substituent of 163, is directed towards solvent, but packs against the carbon-atoms of 
the Arg241 sidechain, providing additional van der Waals interactions. 
 
High-resolution co-crystal structure of m2hTDP2CAT bound to 148  
Raoof et al. also described and characterised two hydroxyphenyl substituents at the R1 
position of the deazaflavin core, in combination with the cyano group at the R3 position:  
compound 147 (3-hydroxyphenol) and 148 (4-hydroxyphenol) with reported EC50 values of 
50 nm and 90 nM respectively [13] (FIGURE 2A). We were successful in obtaining 
diffracting crystals of 148 in complex with m2hTDP2CAT, determining the structure at a 
resolution of 1.7 Angstrom (TABLE 1). In this instance, we also supplemented the 
purification buffers with manganese chloride (iso-structural with magnesium, but readily 
discernible in electron density maps) in order to more fully define any interaction of the 
inhibitors with the metal-dependent catalytic centre of the enzyme. 
 
In the 148 complex the side chains of Arg276 and Asp277 make the same set of 
interactions with the carbonyl and nitrogen groups of the pyrimidodione ring, as with 163.  
However, the side chain of Arg241 occupies a different position, breaking its hydrogen bond 
interaction with Asp277, and instead packing in a π-π interaction against the face of the 
tricyclic core of the deazaflavin (FIGURE 4B, SUPPLEMENTARY FIGURE S2). 
Interestingly, the para-hydroxyl group of the R1 substituent in 148, points directly towards 
the catalytic core of the protein and makes a series of water-mediated contacts to the side 
chains of Asp272 and Asn274.  Electron density maps also clearly showed the position of a 
tartrate molecule (picked up from the crystallisation mother liquor), which is hydrogen-
bonded to the side chain of Ser239, as well as an extensive series of water-mediated 
interactions with several amino acid residues surrounding the catalytic centre.  The tartrate 
																																																								
†		 all numbering is for the mouse protein, the equivalent in human is calculated by subtraction of 10.	
‡	 text in italics represent a ‘humanised’ amino acid residue.	
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molecule also completes the octahedral coordination of the Mn2+ ion (marking the position 
of the catalytic Mg2+ cofactor) (FIGURE 4C).  Moreover, its position marks a potentially 
useful ‘molecular interaction path’ that could be utilised in future iterations of TDP2 inhibitor 
compounds. 
 
Mode of action of deazaflavin inhibitors of TDP2 
Several structures for the catalytic domain of TDP2 in complex with nucleic acid have been 
reported [14, 15]. However, there is disagreement between these structures regarding the 
path that the bound DNA follows across the protein surface; potentially as a result of the 
different substrates used (double vs single-stranded) or possibly due to different crystal 
packing interactions. 
 
However, taking PDB entries 4GZ1 and 4F1H as representative examples of the two 
different modes of TDP2 – product DNA interaction, we note that although the DNA 
trajectories are different (FIGURE 5A) the position of the first (Nuc1) and second 
nucleotides (Nuc2) of the previously modified strand are highly similar in both structures 
(FIGURE 5B).  
 
Regardless of which of these TDP2 — product DNA structures actually represents a 
physiologically relevant binding mode, comparison with the structures reported here shows 
that the deazaflavins occupy a position equivalent to that of Nuc2, with the pendant group 
sitting at the position of the 5’-phosphate, and the deazaflavin core at the position of the 
ribose and base moieties.  
 
Discussion 
The proteins that constitute the DNA Damage Response (DDR) are increasingly being 
recognised as attractive targets for the development of new drugs, which exploit the 
inherent genomic instability found in many cancers [18, 19]. This field has been galvanised 
by the approval of olaparib as a monotherapy for the treatment of specific subsets of 
patients with advanced ovarian cancer.  Olaparib is an inhibitor of the DNA damage sensor 
PARP1, which exploits cancer-associated genetic defects in one DNA repair system 
(homologous recombination-mediated DSB repair) by inhibiting a second system (single-
strand break repair) to achieve potent and selective ‘synthetic lethality’ against tumour cells 
[20]. 
	 10	
 
DDR enzymes that utilise cofactors – such as PARPs or protein kinases for example – fall 
within the traditional canon of drug development targets; i.e. where a specific cofactor-
competitive inhibitor can be readily found. However, many biologically interesting DNA 
repair ‘targets’ for cancer drug discovery lack such cofactors and instead act directly on 
DNA. These present the challenge of discovering compounds capable of out-competing an 
often substantial protein-DNA interaction potentially dominated by highly polar interactions 
with the negatively charged sugar-phosphate backbone. 
 
The discovery of deazflavins as TDP2 inhibitors [13] highlighted the possibility that 
uncharged and ‘drug-like’ competitive inhibitors of DNA binding to a DNA repair enzyme, 
could be found and developed. However, the mode of action of these was unclear, and 
limited further optimisation of these compounds towards clinical development. The 
structural analysis we describe here reveals a very unusual binding mode in which the 
deazaflavin core and pendant groups act as nucleoside mimetics, binding to the 
hydrophobic ‘shelf’ that can support the exposed face of the last base-paired nucleotide at 
the transition from double-stranded to single-stranded DNA in the mouse TDP2CAT — 
product DNA structure (PDB: 4GZ1) Although this deazaflavin series is specific for TDP2, 
many enzymes involved in DNA repair and manipulation engage with a dsDNA-ssDNA 
transition, and structural studies of their complexes with DNA reveal the presence of 
functionally equivalent ‘shelf’ structures that could also provide binding sites for DNA-
competitive small ligands [21-23] that could have utility as selective inhibitors of the DNA 
repair pathways such enzymes mediate.  
 
Interestingly, TDP2 has recently also been identified as a host factor required for the 
replication of picornaviruses in mammalian cells [5]; encoding the essential ‘unlinkase’, 
required to cleave a unique covalent interaction made between the virally-encoded protein 
VPg and RNAs produced by the virion.  It is therefore feasible that small molecule inhibitors 
of TDP2 may also find utility as novel anti-viral agents, for the treatment of picornoviral 
infections; which includes rhinovirus and enterovirus pathogens, both of which produce high 
morbidity rates in infants and children [5, 24]. 
 
It is worth noting here (as previously reported [13]) that deazaflavin-based compounds are, 
in themselves, highly unlikely to be suitable as anti-cancer agents; in most part due to the 
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general inability of the chemical scaffold to penetrate the cell membrane of mammalian 
cells.  However, with the data gleaned from the high-resolution crystal structures presented 
here, we now have a detailed understanding of their mode of action, which will in turn, 
inform the discovery and development of alternative scaffolds, and may eventually lead to 
the conversion of this highly useful ‘tool compound’ into a potential bona fide drug 
candidate for the treatment of disease. 
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MATERIALS AND METHODS 
 
Expression Constructs 
hTDP2CAT 
DNA encoding the catalytic domain of human TDP2 (amino acids 113-362) was cloned into 
pET-28a (Novagen, Merck Chemicals, Nottingham, UK).  Using standard site-directed 
mutagenesis techniques, a single point mutant – Cys273Ser – was subsequently 
introduced into this expression construct; improving the behaviour of the recombinant 
protein, qualitatively with respect to both solubility and aggregation. 
 
mTDP2CAT / m2hTD2CAT 
Synthetic genes codon-optimised for E.coli expression were sub-cloned into a in-house 
modified form of pET-15b, which encodes a N-terminal His-SUMO affinity/solubility tag that 
is cleavable by SENP1 protease (Genscript, Piscataway NJ, USA).  The mTDP2CAT 
expression construct encodes amino acids Leu118-Leu370 of the full-length gene.  The 
m2hTDP2CAT construct encodes the same amino acid range, but with the following series of 
mutations: Glu242Gly, Gln278Arg, Tyr321Cys and His323Leu. 
 
Protein Expression and Purification 
hTDP2CAT 
Transformed colonies of E.coli strain B834(DE3) were used to inoculate a 250-ml flask 
containing 50 ml of Turbo broth (Molecular Dimensions, Newmarket, UK) supplemented 
with kanamycin (50 µg/ml).  The inoculated culture was grown at 37°C, at 220rpm, in an 
orbital shaking incubator until the optical density at 600 nm reached ~1.5.  The culture was 
then stored overnight at 4°C. 
The following day, 20 ml of the overnight culture was used to inoculate a 2-l flask 
containing 1 l of Turbo-broth supplemented with antibiotic as before.  Cultures were grown 
at 37°C, at 220rpm, in an orbital shaking incubator until the optical density at 600 nm again 
reached ~1.5.  Recombinant protein expression was then induced by the addition of 0.4 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and the culture incubated for a further 
3.5 hours at a reduced temperature of 30°C.  Cells were then harvested by centrifugation, 
and the resulting cell pellet stored at -80°C until required. 
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The cell pellet arising from 4 l of culture was resuspended in buffer A: 50 mM 
HEPES.NaOH pH 7.5, 250 mM NaCl, 10 mM imidazole, 0.5 mM TCEP, supplemented with 
protease inhibitors (Roche, Burgess Hill, UK), then disrupted by sonication, and the 
resulting lysate clarified by high-speed centrifugation at 40 000 x g, for 60 minutes at 4°C. 
The supernatant was applied to a batch/gravity flow column containing 10 ml of Talon 
resin (TaKaRa Bio, Saint-Germaine-en-Laye, France) pre-equilibrated in buffer A.  After 
incubation (with rolling) for a period of 1h at 4°C, any unbound material was removed by 
sequential washes with buffer A.  Retained protein was then eluted by application of the 
same buffer supplemented with 300 mM imidazole pH 7.5.   
The eluate was diluted, in order to reduce the salt concentration to < 150 mM NaCl, and 
then applied to a 5ml HiTrap Heparin HP column (GE Healthcare, Little Chalfont, UK) 
equilibrated in buffer B: 50 mM HEPES.NaOH pH7.5, 150 mM NaCl, 1 mM TCEP.  
Unbound material was first removed by application of 5 column volumes of the same buffer.  
Any retained protein was eluted, through application of a linear salt gradient (0.15 to 1 M 
NaCl) to the column. 
A HiLoad 16/600 Superdex 75pg size exclusion column (GE Healthcare) was used to 
purify hTDP2-CAT to homogeneity in 20 mM HEPES.NaOH pH7.5, 300 mM NaCl, 0.5 mM 
TCEP. 
 
mTDP2CAT / m2hTDP2CAT 
A similar protocol was also used to purify both mTDP2CAT and m2hTDP2CAT, with the 
following alterations:  E.coli strain: Rosetta 2(DE3)pLysS (Novagen); antibiotic selection: 50 
µg/ml ampicillin / 34 µg/ml chloramphenicol.  The His-SUMO affinity/solubility tag was 
cleaved overnight at 4°C by the addition of SENP1 protease, after the initial Talon capture 
step. 
 
Thermal Denaturation 
For thermal denaturation, samples containing protein at 1.7 µM and 5 x SYPRO Orange 
(diluted from a 5000 x stock supplied in DMSO; Sigma-Aldrich, Gillingham, UK) were 
prepared in sample buffer: 50mM HEPES.NaOH pH 7.5, 300mM NaCl, 0.5mM TCEP.  
Either DMSO alone, or compound (dissolved in 100% v/v DMSO at its maximum solubility) 
was then added; producing a final concentration of 3% v/v DMSO. Denaturation curves 
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were monitored in 96-well PCR plates using a Roche LightCycler 480 II, with 465 and 580 
nm filters for excitation and emission wavelengths, respectively. The program was as 
follows: 1 min at 20°C, followed by a continuous increment of 0.03°C/s to a final 
temperature of 85°C. Temperature midpoints (Tm) for each folded to unfolded transition 
were determined by non-linear regression fitting of a modified Boltzmann model to 
normalized data in Prism 6.0 (version 6.0h, GraphPad Software, La Jolla, CA USA). 
 
Where: an and ad are the slopes, and bn and bd the y-intercepts, of the native and denatured 
baselines respectively. Tm is the temperature midpoint of the transition from native to 
denatured states, and m represents a generic slope factor. 
 
Fluorescence-based Enzyme Activity Assay 
Substrate oligonucleotide containing a 5’ phosphotyrosine (5’-Y-GATCTAAAAGACT-3’) 
conjugated to Fluorescein isothiocyanate (FITC) was purchased from Midland Certified 
Reagents (Midland, TX, USA). 
 
This assay is a modified version of that reported by [17]. Briefly, enzyme assays were run in 
black 384 well plates, in 50 mM Tris.HCl pH 8.0, 10 mM MgCl2, 80 mM KCl, 0.05% (v/v) 
Tween-20, 1 mM DTT.  50 pmole of hTDP2CAT was combined with 25 nM substrate 
oligonucleotide, in a final volume of 15 µl, for a period of 10 minutes, before addition of 
quench reagents (Gyrasol Technologies, Kansas, USA; sensor diluted 1:15 with enhancer 
buffer).  Fluorescence was subsequently measured in a PHERAstar multimode plate reader 
(BMG Labtech GmbH, Ortenberg, Germany) with an excitation wavelength of 490nm, and 
an emission wavelength of 520nm.  The built-in analysis tools of Prism 6.0 was used to 
examine all experimental data. 
 
Gel-based Enzyme Activity Assay 
This assay is a modified version of that reported by [3, 4].  Briefly recombinant TDP2CAT 
proteins were diluted with reaction buffer: 50 mM Tris-HCl pH 7.5, 50 mM KCl, 1 mM MgCl2, 
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1 mM DTT to produce final concentrations of 1nM (for hTDP2CAT and m2hTDP2CAT) or 3nM 
(for mTDP2CAT) in a volume of 16.2 µl – either in the presence or absence of compound (50 
nM for hTDP2CAT and m2hTDP2CAT, 150 nM for mTDP2CAT; 1% v/v final DMSO 
concentration).  To start the reaction 1.8 µl of radio-labelled 5’ phosphotyrosyl DNA 
substrate was added to the mixture, then incubated at 37 °C.  At 2, 5, and 10 minute time-
points, 6 µl of the reaction mix was withdrawn, and stopped by the addition of formamide 
loading buffer.  Samples were then analysed by denaturing PAGE, visualised by 
phosphorimager, with intensities of substrate and product bands measured by 
GelAnalyzer2010 software (http://www.gelanalyzer.com). 
 
Crystallisation and data collection 
hTDP2CAT 
Crystals of hTDP2CAT were grown at 20 °C in 24-well hanging-drop vapour-diffusion plates, 
mixing 1 µl of protein at 7.5 mg/ml with 1 µl of 100 mM Bis-Tris propane pH 7.0, 0.5 M 
NaCl, 0.05 M magnesium acetate, 1.5% v/v Trimethylamine N-oxide, equilibrated against 
500 µl of the same solution. Crystals were swiped successively through buffers containing 
increasing concentrations of cryo-protectant, before being plunged into liquid nitrogen; 30% 
v/v glycerol was sufficient to prevent ice-formation. 
Diffraction data to 3.1 Å resolution were collected at the Diamond Light Source (DLS, 
Didcot, UK) on beamline I04. Crystals grew in space group P31 2 1, with two molecules of 
hTDP2CAT comprising the asymmetric unit. 
 
hTDP2CAT/163 
Crystals of hTDP2CAT/163 were grown at 20 °C in 24-well hanging-drop vapour-diffusion 
plates, mixing 1 µl of complex (1 : 2.7 molar ratio protein : compound) at ~7.5 mg/ml, with 1 
µl of 1.2M D/L-Malic acid pH7.0, 0.1M Bis-Tris propane pH 7.0, 3% v/v DMSO, equilibrated 
against 500 µl of the same solution. Crystals were swiped successively through buffers 
containing increasing concentrations of cryo-protectant, before being plunged into liquid 
nitrogen; 40% w/v sucrose was sufficient to prevent ice-formation. 
Diffraction data to 3.4 Å resolution were collected at the Diamond Light Source (DLS, 
Didcot, UK) on beamline I04. Crystals grew in space group P65 2 2, with a single molecule 
of hTDP2CAT in complex with 163 comprising the asymmetric unit. 
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m2hTDP2CAT/163 
Crystals of m2hTDP2CAT/163 were grown at grown at 20 °C in 24-well hanging-drop 
vapour-diffusion plates, mixing 1 µl of complex (1 : 2.7 molar ratio protein : compound) at 
~7.5 mg/ml, with 1 µl of 0.1M Bis-Tris propane pH 7.5, 0.2 M sodium citrate, 20% w/v 
PEG3350, 0.3% v/v DMSO, equilibrated against 500 µl of the same solution. Crystals were 
swiped successively through buffers containing increasing concentrations of cryo-
protectant, before being plunged into liquid nitrogen; 8% v/v glycerol + 5% w/v glucose was 
sufficient to prevent ice-formation. 
Diffraction data to 1.8 Å resolution were collected at the Diamond Light Source (DLS, 
Didcot, UK) on beamline I04. Crystals grew in space group P21, with two molecules of 
m2hTDP2CAT, both in complex with 163, comprising the asymmetric unit. 
 
m2hTDP2CAT/148 
Crystals of m2hTDP2CAT/148 were grown at  20 °C in 24-well hanging-drop vapour-diffusion 
plates, mixing 1 µl of complex (1 : 2.7 molar ratio protein : compound) at ~7.5 mg/ml, with 1 
µl of 0.1M Bis-Tris propane pH 6.5, 0.2 M sodium tartrate, 20% w/v PEG3350, 0.3% v/v 
DMSO, equilibrated against 500 µl of the same solution. Crystals were swiped successively 
through buffers containing increasing concentrations of cryo-protectant, before being 
plunged into liquid nitrogen; 8% v/v glycerol + 5% w/v glucose was sufficient to prevent ice 
formation. 
Diffraction data to 1.7 Å resolution were collected at the Diamond Light Source (DLS, 
Didcot, UK) on beamline I04. Crystals grew in space group P21, with two molecules of 
m2hTDP2CAT, both in complex with 148, comprising the asymmetric unit. 
 
Phasing, model building and refinement 
All diffraction data were collected at 100K.  Data were integrated using the software 
package XDS [25], and then processed using the Pointless / Aimless / Ctruncate pipeline of 
the CCP4 software suite [26-28] [29].   Phases were obtained by molecular replacement, 
using PHASER with 4GYZ (mTDP2-CAT) as a search model [30].  An iterative combination 
of manual building in Coot [31] and refinement with either phenix.refine [32] or BUSTER 
[33] produced the final models.  
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Compounds 
Compounds were provided either by the Cancer Research UK Manchester Institute Drug 
Discovery Unit or were re-synthesised in-house by LP or MP, following the published 
protocols [13]. 
 
Accession Numbers 
5J3P, 5J3S, 5J3Z and 5J42 for apo-hTDP2CAT, hTDP2CAT+163, m2hTDP2CAT+163 and 
m2hTDP2CAT+148 respectively. 
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Figure Legends 
	
Figure 1. Structure of the catalytic domain of human TDP2 
(A) Schematic representation of human TDP2, highlighting the relative positions of its 
component domains; where UBA-L = Ubiquitin associated-like domain.  The amino acid 
boundaries of the hTDP2CAT expression construct are indicated by the dotted box.  The 
position of the Cys273Ser mutation introduced to improve protein solubility is also indicated. 
(B) Superposition of TDP2 catalytic domains.  Structures for human, mouse, worm and 
zebrafish TDP2CAT are each shown in ribbon representation.  RMSD values, over the 
indicated number of equivalent atom positions, were calculated using PyMOL 
(www.pymol.org). 
(C) Stereo-view of the X-ray crystal structure of hTDP2CAT.  Molecular cartoons are 
coloured from blue à red, from the visible N- to C-terminus.  The position of the M7-loop or 
motif is additionally highlighted.   
 
Figure 2. Small molecule Inhibitors of human TDP2 
(A) Chemical drawings of four deazaflavin-based inhibitors of human TDP2, as described 
by [13].  Compound numbering and EC50 values are as previously reported. 
(B) Thermal denaturation profiles for hTDP2CAT in the absence or presence of 300 µM 163.  
The experimental data (data points coloured in black) were fitted with a modified Boltzmann 
model to obtain the indicated temperature midpoints (Tm) for the apo- (red curve) or 
liganded forms (blue curve) of the protein. 
(C) Michaelis-Menten Curve for hTDP2CAT using the Fluorescence-based enzyme assay. 50 
pmole of hTDP2CAT was incubated with substrate oligonucleotide for a period of 10 minutes, 
before the addition of Gyrasol reagents.  Experimental data were fitted with a standard 
Michaelis-Menten equation (Prism 6, Graphpad software) in order to determine Km and Vmax 
parameters.  Data points are the mean of 3 independent experiments, with error bars 
representing 1 standard deviation.  
(D) Dose response curves for inhibition of hTDP2CAT by increasing concentrations of the 
indicated deazaflavin.  See associated key for details, and IC50 values determined. Data 
points are the mean of 6 replicates, with error bars representing 1 standard deviation. 
(E) Molecular cartoon highlighting the binding position of 163, relative to the active site of 
hTDP2CAT.  The compound packs against an extended hydrophobic shelf (light grey 
molecular surface + stick representation) formed by the side-chains of Trp297, Thr299, 
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Leu305, Ile307, Cys311, Leu313 and Phe315.   The compound binds at a distance (> 9Å) 
from the active site of the enzyme, as indicated by the sidechains of Asp122 and Glu152, 
and the magnesium cofactor (purple sphere).  
(F) Top; Representative image for the gel-based enzyme activity assay.  hTDP2CAT 
efficiently catalyses the conversion of a 5’ phosphotyrosylated (5’-Y) DNA duplex substrate 
to a 5’ phosphorylated product (5’-P) with time.  Whilst 163 clearly inhibits the human 
enzyme, it is ineffective against the mouse equivalent. Bottom; quantification of gel-based 
assay.  Data represent the mean of three independent experiments, with errors bars 
representing one standard deviation.  
 
Figure 3. The M7-motif of TDP2 
(A) Multiple amino acid sequence alignment for the M7-motif of TDP2.  This region is 
flanked by the two highly conserved ‘TWDT’ (coloured orange) and ‘RFDR’ (coloured cyan) 
motifs.  Amino acid boundaries and UniProt accession codes are as indicated.  Partially 
conserved amino acids are additionally identified by the bold, underlined text.  
(B) Superposition of the M7-motif taken from X-ray crystal structures of human (this study), 
mouse (PDB:4GYZ), zebrafish (4F1H) and worm TDP2 (4FVA).  The spatial arrangement 
of the ‘TWDT’ and ‘RFDR’ motifs is highly conserved.  The loop connecting these two 
elements is conserved in length, but varies somewhat in conformation.  For clarity, 
numbering is only shown for the human protein. 
(C) Molecular cartoon of 163 in complex with hTDP2CAT highlighting the position of two 
amino acid residues (Leu313 and Cys311; black text on white background) that are not 
conserved in the M7-motif of mouse TDP2 (equivalent residues His323 and Tyr231; white 
text on grey background), but are essential for compound binding. 
(D) Top; Representative image for the gel-based enzyme activity assay using m2hTDP2CAT.  
The introduction of four amino acid changes into mTDP2CAT – to generate m2hTDP2CAT – 
restores the inhibitory activity of 163. Labelling as per figure 2D.  Bottom; quantification of 
gel-based assay.  Data represent the mean of three independent experiments, with errors 
bars representing one standard deviation.  
 
Figure 4. Molecular interactions of 163 and 148 with m2hTDP2CAT 
(A) Molecular interactions made by 163. 
(B) Molecular interactions made by 148. 
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(C) The para-hydroxyl of the 148 pendant group makes a series of water-mediated 
interactions with the side chain of Asp 272 and Asn274, in close proximity to the active site 
of the enzyme. 
 
Molecular cartoons are shown throughout, with selected side chains and compounds shown 
in stick representation.  Amino acids labelled in bold italic text, represent those that have 
been mutated from their mouse counterpart, in order to generate m2hTDP2CAT.  Please see 
associated key for details of the colouring scheme. 
 
Figure 5. Deazaflavin binding relative to bound DNA 
(A) The deazaflavin-scaffold interacts with the ‘hydrophobic shelf’ formed by residues of the 
M7-motif.  Molecular surface representations for: (Left) m2hTDP2CAT in complex with 163. 
(Middle) mouse TDP2CAT in complex with a double-stranded product DNA (PDB: 4GZ1). 
(Right) zebrafish TDP2CAT in complex with a single-stranded product DNA (PDB: 4F1H). 
(B) Superposition of structures reveals that the first two nucleotides of either product DNA 
(Nuc1, Nuc2) occupy highly similar positions when bound to TDP2. The dezaflavins occupy 
a position equivalent to Nuc2, with the pendant group sitting at the position of the 5’-
phosphate, and the deazaflavin core at those of the ribose and base moieties.  
 
In both panels, the carbons of the previously modified 5’ nucleotide are coloured yellow, 
and those of the deazaflavin 163 in green.  
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Table 1.   Data collection and refinement statistics  
 
 hTDP2-CAT 
PDB: 5J3P 
hTDP2-CAT + 163 
PDB: 5J3S 
m2hTDP2-CAT + 163 
PDB: 5J3Z 
m2hTDP2-CAT + 148 
PDB: 5J42 
Data collection     
Space group P 31 2 1 P 65 2 2 P 21 P 21 
Cell dimensions     
    a, b, c (Å) 92.54, 92.54, 119.07 68.52, 68.52, 209.51 61.00, 42.80, 108.75 61.05, 42.87, 109.05 
  α, β, γ (°)  90, 90,120 90, 90, 120 90, 94.15, 90 90, 94.05, 90 
Resolution (Å) 47.79-3.10 (3.31-3.10)* 45.22-3.40 (3.67-3.40) 42.8-1.80 (1.84-1.80) 42.07-1.70 (1.73-1.70) 
Rmerge 0.133 (0.731) 0.256 (1.876) 0.051 (0.166) 0.043 (0.810) 
Rmeas 0.170 (0.932) 0.299 (2.185) 0.072 (0.233) 0.061 (1.133) 
Rpim 0.103 (0.571) 0.168 (1.111) 0.050 (0.164) 0.042 (0.791) 
Mn I /  σI 9.6  (1.7) 6.4 (1.1) 9.7 (2.0) 16.3 (1.0) 
CC1/2 1.00 (0.94)
‡ 0.99 (0.54) 0.99 (0.87) 1.00 (0.60) 
Completeness (%) 99.8 (99.7) 99.9 (100) 98.0 (79.7) 99.2 (98.9) 
Multiplicity 4.8 (4.9) 6.3 (6.8) 2.9 (2.1) 3.1 (3.2) 
     
Refinement     
Resolution (Å) 47.79-3.10 45.22-3.40 42.8-1.80 42.07-1.70 
No. unique reflections 11128 7545 51379 112934 
Rwork / Rfree 0.26 / 0.30 0.25 / 0.27 0.17/ 0.20 0.16 / 0.20 
No. atoms     
    Protein 3553 1732 3992 3968 
    Ligand/ion 8 29 168 142 
    Water 7 --- 604 693 
B-factors     
    Protein 98.2 119.9 23.5 26.6 
    Ligand/ion 84.3 78.7 42.1 30.9 
    Water 43.4 -- 40.7 44.9 
R.m.s. deviations     
    Bond lengths (Å) 0.002 0.001 0.008 0.020 
    Bond angles (°) 0.551 0.435 0.98 1.654 
     
Reference model§ 4GYZ 4GYZ N/A N/A 
 
Ramachandran 
Outliers (%) 
Favoured (%) 
 
 
 
5 
92.4 
 
 
2 
92.6 
 
 
0 
97.9 
 
 
0 
97.9 
MolProbity score 1.8 1.9 1.28 1.50 
 
* Values in parentheses are for highest-resolution shell 
‡ 
Data isotropic to this resolution 
§ 
PDB entry used as ‘reference model’ during refinement 
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Figure S1. Gyrasol reagent-based enzyme assay 
(A) Chemical drawing of the Fluorescein isothiocyanate (FITC) - 5’ phosphotyrosyl linkage. 
(B) Progression curve for hTDP2CAT. Increasing concentrations of enzyme (as indicated) were incubated with a 
fixed concentration of substrate, and the change in fluorescence monitored over time.  Data points are the 
mean of 9 measurements, with error bars representing 1 standard deviation. 
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A
Figure S2.  Representative omit electron density maps 
(A) hTDP2CAT + 163.  2mFo-DFc map contoured at 1.2σ (grey mesh), mFo-DFc  contoured at 3σ (green mesh). 
(B) m2hTDP2CAT + 163. 2mFo-DFc map contoured at 1.2σ (grey mesh), mFo-DFc contoured at 3σ (green mesh). 
(C) m2hTDP2CAT + 148. 2mFo-DFc map contoured at 1.2σ (grey mesh), mFo-DFc contoured at 3.5σ (green mesh).  
 
In each case, in order to to generate the maps, the ligand has been excluded from refinement.  
Density for ligand in each 2mFo-DFc map has been suppressed, in order to improve the figure clarity.   
Amino acid side chains are show in stick representation, with carbon atoms coloured in cyan.   
Compounds are also shown in stick representation, with carbon atoms coloured in green.  
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Figure S3.  The binding mode of 163 is identical in hTDP2CAT and m2hTDP2CAT 
A superposition of the two structures is shown in molecular cartoon representation. 
See associated key for colour scheme.
